As of 2025-10-24, the EV/EBITDA ratio of Apellis Pharmaceuticals Inc (APLS) is -19.02. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apellis's latest enterprise value is 3,613.16 mil USD. Apellis's TTM EBITDA according to its financial statements is -189.98 mil USD. Dividing these 2 quantities gives us the above Apellis EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 13.4x | 10.6x |
| Forward P/E multiples | 10.4x - 22.3x | 13.6x |
| Fair Price | (15.61) - (20.13) | (18.20) |
| Upside | -154.6% - -170.4% | -163.6% |
| Date | EV/EBITDA |